Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic ...

“We are very excited about the potential for the OX40 mechanism. With the goal of creating the overall best OX40 program, we intentionally have designed STAR-0310 to capitalize on the learnings ...

KY1005 works by bonding to the OX40-Ligand (OX40-L), which forms an important part of the process that activates the immune system. Interaction between OX40-L and its binding partner OX40 have ...